Savara (SVRA)
(Delayed Data from NSDQ)
$4.46 USD
-0.12 (-2.62%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Savara Inc. [SVRA]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Savara Inc.
Industry: Medical - Drugs
IMPALA-2 Phase 3 Trial Hits Primary Endpoint For Molgramostim -KOL Thoughts on Data; Reit. Buy; Increasing PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Views on Clinical Progress in the Respiratory Field
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Optimistic on Near-Term Topline Molgramostim Data; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim Near-Term Pivotal IMPALA-2 Topline Expected 2Q24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Savara Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim Advances With Phase 3 IMPALA-2 Topline Expected 2Q24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim Pivotal IMPALA-2 Progress-Positioned for Success; PT Up to $6, Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Capitalized Beyond Pivotal aPAP Readout, IMPALA-2 Continues Onward; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Steady As She Goes-Phase 3 IMPALA-2 Trial on Track in aPAP; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Pivotal IMPALA-2 Trial in aPAP Continues As Planned; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim IMPALA-2 Trial Remains on Track?Capitalized Through aPAP Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Continued Pivotal IMPALA-2 Progress For Nebulized Molgramostim in aPAP
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Steady As She Goes-Pivotal Molgramostim aPAP Progress; Opportunity for IMPALA-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Progress Forward for Molgramostim in aPAP Remains on Track; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Company: Savara Inc.
Industry: Medical - Drugs
Company: Savara Inc.
Industry: Medical - Drugs
Refocused Strategy has IMPALA-2 at the Forefront Leading With Dosing of Patients Expected in 2Q/3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Platform Refocused on Molgradex as the Path Forward; PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
IMPALA-2 Trial Design Finalized With 1Q21 Initiation; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A